HomeResearch & Knowledgeback to HomeChinaback to Research & Knowledge解读中国下一波创新浪潮back to China

Video

解读中国下一波创新浪潮

6 min.

May 2019

近年来，许多中国公司已成为备受瞩目的全球创新公司。但在中国还有一群更低调的公司：成千上万家创新型公司正悄无声息地颠覆众多行业，超越现有企业，开发出新的产品和新的商业模式。

最近，IMD的Mark J. Greeven教授和帝国理工学院商学院的George S. Yip.教授，以及GSL Innovation的首席执行官Wei Wei针对中国的下一波创新公司展开了一项调查。他们专门针对中国制定了一个新兴创新公司的框架，详细介绍了中国不同类型的创新公司，以及非中国跨国公司的经验教训。

他们的调查结果发表在《麻省理工学院斯隆管理评论》上，标题为：解读中国下一波创新浪潮。在这篇文章中，他们引用了其最近发表著作中的见解，即《先驱、隐形冠军、变革者和弱势者：从中国创新者身上吸取的经验教训》（麻省理工学院出版社）。

在这个新的“IMD研究和知识”视频系列中，IMD教师从最近发表的有影响力的研究性文章中，探索令人意外的结果，并为商业领导者阐明了主要的学习要点。

这股新的创新者浪潮如何影响您的公司？

观看视频并找出答案。

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Keep reading

Article

A strategic thinking test for leaders - Brain Circuits

Take the strategic thinking test for leaders to assess your readiness and explore practical steps to strengthen this vital leadership capability.

Leadership Strategy

By Michael D. Watkins

in I by IMD

Article

Energy transition: how to surf the wave of change

Future-ready organizations that focus on the energy transition and accelerate along with it will reap the benefits.

Change Management Strategy Sustainability

By Julia Binder and Knut Haanaes

in I by IMD

Case Study

Sandoz (B): The art of staying true to your mission

Strategy Leadership Global Business

By Jim Pulcrano, Charan Singh, Zita Falk, Franciska Darmer and Barbara Schmidt-Ley

Case Study

Sandoz China: Do we stay or do we go?

Strategy China Leadership

By Mark J. Greeven and Jim Pulcrano

Case Study

Sandoz (A): Breaking free to stand alone

Strategy Leadership Global Business

By Jim Pulcrano, Charan Singh, Zita Falk, Franciska Darmer and Barbara Schmidt-Ley

Video

Lean and clean are perfect partners, says CEO of engineering giant

ABB CEO Morten Wierod on leaner cleaner strategy, electrification, automation, robotics, AI, digital transformation, sustainability, leadership.

Leadership Strategy Sustainability

By Jean-François Manzoni

in I by IMD

Article

LLMs will hallucinate forever – here is what that means for your AI strategy

OpenAI’s new paper shows AI hallucination is inevitable. Discover how Gödel’s paradox reshapes AI strategy and leadership for 2026 and beyond.

Five ways to unlock breakthrough ideas

New ideas behind innovative business models can feel sudden, but are rarely random. Innovation happens when you reframe challenges and opportunities.

Generation of Givers - Family Business

Discover how family business leaders can nurture a generation of givers, ensuring wealth transfer builds lasting impact.

Family Business Leadership Strategy

By Camille Korschun, Peter Vogel and Martin Euwema

in I by IMD

Article

How to be remembered for the right reasons #5: Create shared connection

Earn the right to be heard by blending credibility with relatability, meeting audiences where they are, and building rapport through shared stories.

Leadership Strategy

By Robert Vilkelis

in I by IMD Brain Circuits

4 September 2025

Energy transition: how to surf the wave of change

By Julia Binder and Knut Haanaes
in I by IMD

Summary

Future-ready organizations that focus on the energy transition and accelerate along with it will reap the benefits.

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Change Management

Strategy

Sustainability

Browse all topics

Sandoz (B): The art of staying true to your mission

By Jim Pulcrano Charan Singh Zita Falk Franciska Darmer and Barbara Schmidt-Ley
Case reference: IMD-2670 ©2025

Summary

This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case B looks at Sandoz once it has become independent. The hard work of figuring out the best way to spin off is done, a new strategy created, and some difficult choices made. But now how will CEO Richard Saynor and his leadership team ensure that Sandoz is fit for purpose?

Reference IMD-2670

Organization Sandoz

Industry Healthcare, Pharmaceuticals

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Strategy

Leadership

Global Business

Browse all topics

Sandoz China: Do we stay or do we go?

By Mark J. Greeven and Jim Pulcrano
Case reference: IMD-2680 ©2025

Summary

The Sandoz leadership team faced an important decision as it broke away from Novartis and became a public company. Should Sandoz retain the global geographical coverage it had had in its many years as part of Novartis? Or should it focus on fewer geographies and a simplification of the business models it was using? Since Sandoz was in a lower margin business than an innovator pharma company like Novartis, eventually, the senior leadership team decided to exit China. There was a belief that it was going to be difficult to compete on price with local Chinese companies, and the investment required to invest in more complex generics, as well as high-margin biosimilars, was beyond the means of Sandoz as it became a publicly listed company. The case also touches on the differences of opinion in a very strong leadership team and the options that were explored, or not, as the sale of Sandoz China to Aspen Pharmacare was concluded.

Reference IMD-2680

Organization Sandoz

Industry Healthcare, Pharmaceuticals

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Strategy

China

Leadership

Browse all topics

Sandoz (A): Breaking free to stand alone

By Jim Pulcrano Charan Singh Zita Falk Franciska Darmer and Barbara Schmidt-Ley
Case reference: IMD-2669 ©2025

Summary

This case series explores Sandoz's spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor's (CEO, Sandoz) ruminations as he builds the company strategy in preparation for the board's approval of Sandoz as a standalone company. The narrative outlines the key strategic areas that Richard, along with his senior leadership team, considered and which strategy was eventually approved by the board of directors (i.e. product portfolio mix), the direction of the growth strategy (i.e. top vs. bottom line approach), target geography regions and ownership model. Case A focuses on the dilemmas and considerations of each strategic area.

Reference IMD-2669

Organization Sandoz

Industry Healthcare, Pharmaceuticals

Available Languages English

Contact

Research Information & Knowledge Hub for additional information on IMD publications

Related topics

Strategy

Leadership

Global Business

Browse all topics

Lean and clean are perfect partners, says CEO of engineering giant